|  | RMST at times (years) | | | | Survival proportions at times (years) | | |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Treatment | Source | 4 | 8 | 15 | 4 | 8 | 15 |
| FC | Observed | 3.56 | 5.99 |  | 0.77 | 0.41 |  |
|  | Semi-Markov: SPM (Williams 2017) | 3.50 | 5.47 | 6.46 | 0.70 | 0.30 | 0.05 |
|  | Semi-Markov: FPM | 3.63 | 6.05 | 8.12 | 0.77 | 0.46 | 0.18 |
|  | Microsimulation: SPM, ASF | 3.51 | 5.59 | 6.81 | 0.72 | 0.33 | 0.08 |
|  | Microsimulation: FPM, ASF | 3.57 | 6.27 | 9.26 | 0.77 | 0.56 | 0.34 |
|  | Microsimulation: FPM, RSF | 3.57 | 6.27 | 9.14 | 0.78 | 0.55 | 0.31 |
| RFC | Observed | 3.68 | 6.54 |  | 0.84 | 0.61 |  |
|  | Semi-Markov: SPM (Williams 2017) | 3.64 | 5.80 | 6.68 | 0.77 | 0.32 | 0.03 |
|  | Semi-Markov: FPM | 3.63 | 6.05 | 8.20 | 0.77 | 0.46 | 0.21 |
|  | Microsimulation: SPM, ASF | 3.63 | 5.82 | 6.81 | 0.77 | 0.32 | 0.05 |
|  | Microsimulation: FPM, ASF | 3.67 | 6.52 | 9.48 | 0.82 | 0.58 | 0.31 |
|  | Microsimulation: FPM, RSF | 3.67 | 6.52 | 9.38 | 0.82 | 0.58 | 0.29 |
| RMST, restricted mean survival time; FC, fludarabine and cyclophosphamide; RFC, rituximab, fludarabine, and cyclophosphamide; SPM, standard parametric models; FPM, flexible parametric models; ASF, all-cause survival framework; RSF, relative survival framework. | | | | | | | |